JeffreyL.WolfMD
Oncology • San Francisco, CAHematologic Oncology
Assistant Clinical Professor of Medicine, UCSF
Dr. Wolf is on Doximity
As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
400 Parnassus Ave Ste A502
San Francisco, CA 94143Phone(415) 353-2421
Fax(415) 353-2545- Is this information wrong?
Education & Training
UCSFFellowship, Hematology, 1976 - 1978
University of California San DiegoResidency, Internal Medicine, 1975 - 1976- University of California San DiegoResidency, Internal Medicine, 1972 - 1974
University of Illinois College of MedicineClass of 1972
Certifications & Licensure
CA State Medical License 1973 - 2023- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Super Doctor SuperDoctors.com
Clinical Trials
- A Phase 1 Study Evaluating CB-5083 in Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2014 Sep 01Nooka, A.K.,Cesano, A.,Krishnan, A.,Ramsey, B.,Siegel, D.,Wolf, J.,Barron, K.,McBride, L.,Duarte, L.,Billena, M.,Vij, R.
- A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship Between Patient Outcomes, Treatment Regimens and Molecular Profiles Start of enrollment: 2011 Jul 01Ailawadhi, S.,Bar, M.,Belani, R.,Berdeja, J.,Castine, M.,Center, Q.C.,Cho, J.,Faber, E.,Fay, J.,Geller, R.,Harrison, B.,Jagannath, S.,Kirby, S.,Lonial, S.,Meehan, K.,Orloff, G.,Robles, R.,Siegal, D.,Steis...
- A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan and Bolus Etoposide as Preparative Therapy for Patients With Acute Myeloid Leukemia Undergoing Autologous Stem Cell Transplantation Start of enrollment: 2009 Nov 01Martin, T.
Publications & Presentations
PubMed
- Are Antimotility Agents Safe for Use in Clostridioides difficile Infections? Results From an Observational Study in Malignant Hematology Patients.Carla Kuon, Rae Wannier, David G. Sterken, Margaret C. Fang, Jeffrey L. Wolf, Priya A. Prasad> ;Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2020 Nov 5
- Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantationMariam T. Nawas, Ying Sheng, Chiung Yu Huang, Charalambos Andreadis, Thomas G. Martin, Jeffrey L. Wolf, Weiyun Z. Ai, Lawrence D. Kaplan, Gabriel N. Mannis, Aaron C Lo...> ;Journal of Geriatric Oncology. 2020 Oct 13
- The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.Maria-Teresa Cedena, Estela Martin-Clavero, Sandy W. Wong, Nina Shah, Natasha Bahri, Rafael Feito Alonso, Carmen Barcenas, Antonio Valeri, Johny Salazar Tabares, Jose ...> ;PLOS ONE. 2020 Aug 31
- Join now to see all
Abstracts/Posters
- Profiling the Cell Surface Landscape of Proteasome Inhibitor-Treated and _Resistant Multiple Myeloma to Guide Immunotherapy Targeting, Diagnosis, and BiologyJeffrey L. Wolf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Germline Variation Predicts Treatment Response in Multiple MyelomaJeffrey Lee Wolf, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative NeoplasmApril 11th, 2018
Measurable Residual Disease Could Improve Multiple Myeloma Treatment DecisionsDecember 8th, 2020
Hospital Affiliations
UCSF Medical CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
